We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




D‐dimer Levels Predict Ischemic Stroke in Infective Endocarditis

By LabMedica International staff writers
Posted on 17 Feb 2020
Print article
Image: Blood test for D-dimer showed high sensitivity and specificity in the prediction of ischemic stroke in patients with infective endocarditis (Photo courtesy of Blue Horizon).
Image: Blood test for D-dimer showed high sensitivity and specificity in the prediction of ischemic stroke in patients with infective endocarditis (Photo courtesy of Blue Horizon).
Infective endocarditis (IE) is a life‐threatening disease, especially in developing countries. IE may present many extra‐cardiac symptoms or signs, in which neurological complications are the most prominent and severe.

The manifestations of these neurological complications include ischemic stroke, hemorrhagic stroke, mycotic aneurysms, brain abscesses, meningitis, and encephalitis. Ischemic stroke, characterized by the interruption of cerebral blood flow, is a dominant and frequent neurological complication of left‐sided IE, as well as the main stroke type among all stroke cases in IE.

Infectious disease specialists at the Tianjin Medical University General Hospital (Tianjin, China) enrolled in a prospective study, a total of 173 consecutive patients with IE from January 2016 to December 2018. All patients were hospitalized for the first time with a definite diagnosis of IE based on the modified Duke criteria. The primary diagnosis of ischemic stroke was mainly based on clinical neurological symptoms and imaging manifestations on brain magnetic resonance imaging (MRI).

The team performed the measurement of plasma D‐dimer on admission using the VIDAS D‐dimer assay (bioMérieux, Marcy-l'Étoile, France), which has shown comparable sensitivity and specificity. The normal range of plasma D‐dimer is 0‐500 μg/L. Other hematological and biochemical data, such as white blood cell (WBC) count and C‐reactive protein (CRP), were also detected from peripheral blood samples collected on the next morning after admission. In addition, to identify causative organisms, at least three sets of blood cultures were obtained from all patients before the initiation of antibiotic therapy.

The scientists reported that ischemic stroke was observed in 38 (22%) patients during 6‐month follow‐up since definite diagnosis of IE. Patients with ischemic stroke had significantly higher levels of plasma D‐dimer than those of patients without stroke (4,982 versus 2,205 μg/L). Positive results of blood cultures were obtained from 107 (62%) patients. Streptococcus identified in 40 (23%) patients was the most common microorganism, accounting for 37% of all positive blood cultures. The secondary dominant causative agent was Staphylococcus aureus, isolated in 33 (19%) patients and 31% of all positive blood cultures.

In addition, Staphylococcus aureus infection (Hazard Ratio (HR): 1.96), mitral valve vegetation (HR: 1.52), and higher levels of on‐admission plasma D‐dimer (HR: 1.35) were significantly associated with ischemic stroke. Moreover, D‐dimer levels ≥3,393 μg/L served as a strong predictor for ischemic stroke in patients with IE, and the sensitivity and specificity were 78% and 83%, respectively.

The authors concluded that their study revealed that higher levels of on‐admission plasma D‐dimer showed high sensitivity and specificity in the prediction of ischemic stroke, which occurred mostly in the first three months after the diagnosis of IE. On the one hand, as a traditional and inexpensive biomarker, plasma D‐dimer may help clinicians identify high‐risk IE patients for ischemic stroke in a simple and quick way. The study was published on February 3, 2020 in the Journal of Clinical Laboratory Analysis.

Related Links:
Tianjin Medical University General Hospital
bioMérieux


New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit
New
Uric Acid and Blood Glucose Meter
URIT-10

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.